Proniras is a specialty pharmaceutical company focused on the development of drugs for neurological conditions with high unmet medical need. The Company’s lead program is tezampanel, a novel AMPA/kainate receptor antagonist which antagonizes glutamate signaling in the central nervous system (CNS). Glutamate is the predominant excitatory neurotransmitter in the CNS and, in the context of opiate abuse, plays a pivotal role in ...
Proniras is a specialty pharmaceutical company focused on the development of drugs for neurological conditions with high unmet medical need. The Company’s lead program is tezampanel, a novel AMPA/kainate receptor antagonist which antagonizes glutamate signaling in the central nervous system (CNS). Glutamate is the predominant excitatory neurotransmitter in the CNS and, in the context of opiate abuse, plays a pivotal role in withdrawal symptoms. Upon abrupt cessation of opioid use, a glutamate-driven over-agitation of the nervous system develops and leads to excruciating physical and psychological symptoms in withdrawal.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.